Agios Pharmaceuticals (AGIO) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Agios Pharmaceuticals (AGIO) has outperformed Perrigo (PRGO) over the past year, losing 22.2% versus a loss of 32.9%. Over five years, AGIO leads with a -31.3% price change compared with -67.5% for PRGO. Perrigo is the larger company by market cap ($2.01 billion vs $1.90 billion), about 1.1 times the size.
Perrigo pays a dividend yielding 7.97%, while Agios Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | PRGO |
|---|---|---|
| Share price | $31.79 | $14.55 |
| Market cap | $1.90B | $2.01B |
| 1-day change | +0.22% | +3.93% |
| YTD return | +16.79% | +4.53% |
| 1-year return | -22.22% | -32.89% |
| 5-year return | -31.31% | -67.46% |
| Forward P/E | — | 6.07 |
| EPS (TTM) | $-7.03 | $-12.28 |
| Dividend yield | 0.00% | 7.97% |
| Annual dividend | $0.00 | $1.16 |
| 52-week high | $46.00 | $22.02 |
| 52-week low | $22.24 | $9.23 |
| Distance from 52-week high | -30.89% | -33.92% |
| Analyst consensus | buy | none |
| Avg. price target upside | +44.70% | +13.40% |
| Average volume | 1.04M | 2.81M |
| Shares outstanding | 59.70M | 138.37M |
| Employees | 539 | 8,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGIO has outperformed PRGO by 10.7 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.97% vs 0.00%).
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
AGIO vs PRGO FAQ
Which is bigger, Agios Pharmaceuticals or Perrigo?
Perrigo (PRGO) is larger, with a market capitalization of $2.01B compared with $1.90B for Agios Pharmaceuticals (AGIO).
Which stock has performed better over the past year, AGIO or PRGO?
AGIO returned -22.22% over the past 12 months, compared with -32.89% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Agios Pharmaceuticals or Perrigo?
Perrigo pays a dividend yielding 7.97%, while Agios Pharmaceuticals does not currently pay a regular dividend.
Are Agios Pharmaceuticals and Perrigo in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.